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SARS-CoV-2–induced Acute Respiratory Distress
Syndrome: Pulmonary Mechanics and
Gas-Exchange Abnormalities
To the Editor:
In January 2020, the first cases of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection were reported in Europe.
Multiple outbreaks have since then led to a global pandemic, as well
as to massive medical, economic, and social repercussions (1, 2).
SARS-CoV-2 pneumonia can develop into acute respiratory
distress syndrome (ARDS) when mechanical ventilation (MV) is
needed (3, 4). ARDS produces abnormalities in gas exchange with a
variable degree of shunt (5), high dead space ventilation (dead space
volume [VD]/tidal volume [VT] ratio) (6), diminished pulmonary
compliance (7), and alterations to the pulmonary circulation (8).
The cornerstone of ARDS management is to provide adequate gas
exchange without further lung injury as a result of MV. To date,
information regarding the characteristics of SARS-CoV-2–induced
ARDS is not completely known. However, this information is
crucial to better apply MV and facilitate organ support strategies.
We therefore present the characteristics of gas exchange,
pulmonary mechanics, and ventilatory management of 50 patients
with laboratory-confirmed SARS-CoV-2 infection, who developed
ARDS and underwent invasive MV (IMV).
Methods
Descriptive analysis included 50 consecutive patients with
laboratory-confirmed SARS-CoV-2 infection who developed ARDS
(9) and underwent IMV. These patients were admitted to the SARS-
CoV-2–dedicated intensive care units (ICUs) at Hospital Clinic of
Barcelona, Spain, between March 7 and March 25, 2020.
Upon ICU admission, epidemiological characteristics, the
severity of SARS-CoV-2 infection with the Acute Physiology and
Chronic Health Evaluation II score, prognostic biomarkers of
SARS-CoV-2 infection (described in Reference 4), time from
hospital to ICU admission, time from ICU admission to intubation,
oxygen therapy or noninvasive ventilation (NIV) use, and
microbiology were investigated.
On the day that criteria for ARDS diagnosis were met (9) and
IMV was needed, the following assessments were performed:
impairment in oxygenation was analyzed with the partial pressure
of oxygen (PaO2)/fraction of inspired oxygen (FIO2) ratio, and
abnormalities of CO2 metabolism were studied with the ventilatory
ratio (VR), a surrogate parameter of VD/VT (10).
In addition, adjunctive therapies and MV parameters related
with ventilation-induced lung injury (VILI) described elsewhere
(11–15) were investigated.
Table 1. Characteristics of 50 patients with SARS-CoV-2–
induced ARDS
Characteristic Median (IQR) or n (%)
Baseline characteristics
Age, yr 66 (57–74)
Male 36 (72)





Alcohol consumption habit 6 (12)
APACHE II score at ICU admission 13 (11–18)
SOFA score upon ARDS diagnosis 7 (6–9)
Time from hospital admission to ICU admission, d 2 (1–3.75)
Time from ICU admission to intubation, d 1 (0–1)
Coinfection 2 (4)
Oxygen therapy and NIV before intubation†
Venturi and nonrebreathing oxygen mask 43 (93)







Prone position 11 (22)
Neuromuscular blockade use 24 (48)
Recruitment maneuvers 18 (36)
Vasopressor use 16 (32)
Corticosteroid therapy 18 (36)
Laboratory findings‡
Hemoglobin, g/dl 12.80 (11.83–13.40)
White blood cell count, 3109/L 8.11 (6.26–11.42)
Lymphocyte count, 3109/L 0.60 (0.40–0.90)
Platelet count, 3109/L 219 (174–274)
(Continued)
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Correlations of SARS-CoV-2 prognostic biomarkers (4),
pulmonary mechanics, and gas-exchange data were performed.
Twenty-eight–day and hospital mortality, ventilator- and ICU-free
days at Day 28, hospital and ICU lengths of stay, and need for
tracheostomy were also evaluated (16). Finally, a subanalysis assessing
differences before and after prone positioning was performed. For
additional detail on the method, see the online supplement.
Results
By March 25th, 2020, 50 patients with laboratory-confirmed SARS-
CoV-2 infection and ARDS had been admitted to our hospital. Table 1
shows the demographic and clinical characteristics of these patients. The
median (interquartile range [IQR]) age was 66 (57–74) years. Thirty-six
patients (72%) were men. Upon ARDS diagnosis, 44% of patients were
initially classified as having moderate ARDS, whereas 24% were
classified as havingmild ARDS and 32%were classified as having severe
ARDS. The outcomes of these patients are shown in Table 1. ICU and
hospital lengths of stay were prolonged, and tracheostomy was
performed in 30 (60%) patients. Hospital mortality was 34%.
Table 2 shows the results for gas exchange, pulmonary
mechanics, and variables associated with VILI upon ARDS
diagnosis. Excluding baseline mechanical power, other MV
parameters associated with VILI were within normal range.
There was no correlation between PaO2/FIO2 and the static
compliance of the respiratory system (Crs) (Figure 1A).
Notwithstanding, a weak yet significant correlation was found
between VR and both positive end-expiratory pressure and end-
inspiratory plateau pressure (Figures 1C and 1D).However,
D-dimer was not significantly correlated with VR (Figure 1B).
Eleven patients underwent prone positioning on the day of
ARDS diagnosis (see Table E1 in the online supplement). On
average, PaO2/FIO2 increased from the supine to the prone position
by 159 (IQR, 32–143; P= 0.002). Significant differences were also
found in Crs between supine to prone position with an increase of
15.45 (IQR, 4.32–18.25; P= 0.015).
Discussion
SARS-CoV-2–induced ARDS produced an impairment in gas
exchange and pulmonary mechanics comparable with those of prior
cohorts with non–SARS-CoV-2 ARDS (10, 13, 17, 18). As in other
studies, VR was high, and the most frequent presentation was
moderate ARDS (10, 17, 19). On average, Crs in the cohort with SARS-
CoV-2–induced ARDS was also found to be comparable, but with
remarkable heterogeneity (13, 18). Other studies have reported similar
(20), higher (21), or lower Crs (19, 22, 23) in SARS-CoV-2–induced
ARDS. As Crs decreases alongside the collapse of alveolar units due to
lung edema, several factors may provide explanations for such
reported differences, including treatments, intubation strategies, and
the stage of the disease. In our cohort with early SARS-CoV-2–induced
ARDS, the time from ICU admission to intubation was only 24 hours,
despite the use of high-flow nasal cannula or NIV in some cases.
Table 2. Gas exchange, pulmonary mechanics, and VILI of 50





PaCO2, mm Hg 47 (42.9–53.4)
PaO2, mm Hg 107 (88.5–133.6)
PaO2/FIO2 174 (128–232)
Ventilatory ratio* 1.93 (1.55–2.23)
Ventilator settings, pulmonary mechanics, and
other variables associated with VILI
VT/PBW, ml/kg 6.78 (6.30–7.32)
Respiratory rate, breaths/min 22 (20–23)
PEEP, cm H2O 13 (11–14)
FIO2, % 62 (53–76)
Peak inspiratory pressure, cm H2O 32 (29–34)
End-inspiratory plateau pressure, cm H2O 23 (21–25)
Driving pressure, cm H2O
† 11 (9–13)
Mechanical power, J/min‡ 22.32 (18.49–28.10)
Crs, ml3 cm H2O
21x 40.13 (32.88–51.68)
Definition of abbreviations: ARDS=acute respiratory distress syndrome;
Crs= static compliance of the respiratory system; FIO2 = fraction of inspired
oxygen; IQR= interquartile range; PaCO2 = partial pressure of carbon
dioxide; PaO2 = partial pressure of oxygen; PBW=predicted body weight;
PEEP=positive end-expiratory pressure; SARS-CoV-2= severe acute
respiratory syndrome coronavirus 2; VILI = ventilation-induced lung injury;
VT = tidal volume.
*Ventilatory ratio is defined as (minute ventilation [ml/min]3PaCO2
[mm Hg])/(PBW3 100337.5).
†Driving pressure is the difference between plateau pressure and PEEP.
‡Mechanical power was calculated following previously published
formulas (11).
xCrs is the ratio of tidal volume to driving pressure.
Table 1. (Continued )
Characteristic Median (IQR) or n (%)
Creatinine, mg/ml 0.98 (0.77–1.45)
Sodium, mEq/L 138 (136–140)
Potassium, mEq/L 3.90 (3.60–4.30)
Aspartate aminotransferase, U/L 65 (48–82)
Alanine aminotransferase, U/L 45 (28–76)
Total bilirubin, mg/dl 0.50 (0.40–0.90)
g-Glutamyltransferase, U/L 54 (36–105)
Lactate, mmol/L 1.33 (1–1.59)
Alkaline phosphatase, U/L 67 (53–86)
Lactate dehydrogenase, U/L 442 (386–541)
Albumin, g/L 36 (33–38)
D-dimer, ng/ml 1,100 (800–3,800)
Ferritin, ng/ml 1,436.50 (951.25–2,149.25)
Procalcitonin, ng/ml 0.27 (0.17–0.97)
C-reactive protein, mg/dl 15.68 (9.64–27.03)
Outcomesx
Hospital mortality 15 (34)
Mortality at Day 28 10 (20)
Ventilator-free at Day 28, d 9 (0–16)
ICU-free at Day 28, d 0 (0–9)
Hospital length of stay, d 36 (24–44)
ICU length of stay, d 26 (17–34)
Tracheostomy 30 (60)
Definition of abbreviations: APACHE II = Acute Physiology and Chronic
Health Evaluation II; ARDS=acute respiratory distress syndrome;
BMI =body mass index; ICU= intensive care unit; IQR= interquartile range;
NIV= noninvasive ventilation; SARS-CoV-2= severe acute respiratory
syndrome coronavirus 2; SOFA= sequential organ failure assessment.
*Missing data from nine patients.
†Missing data from four patients.
‡Laboratory findings upon ARDS diagnosis.




We found no correlation between Crs and PaO2/FIO2. Crs
estimates the amount of aerated lung volume in ARDS (7). These
results might therefore suggest that the proportion of nonaerated or
poorly aerated to well-aerated lung volume is not the only
determinant for such a degree of hypoxemia. This may not be specific
to SARS-CoV-2–induced ARDS, as other factors apart from the amount
of aerated lung tissue (i.e., lung perfusion) are largely known to influence
pulmonary shunt (24). However, some authors have reported that lung
perfusion in SARS-CoV-2–induced ARDS is more impaired than ARDS
by other causes (21). We identified remarkable abnormal lung
perfusion in computed tomographic scans performed in these patients
(Figure E1).
We found no correlation between D-dimer and VR, suggesting
that high VD/VT might not be related to a coagulation disorder
(i.e., pulmonary microthrombosis). Nonetheless, as suggested by its
association with VR, high end-inspiratory and end-expiratory
pressures (i.e., mean airway pressures) could increase VD/VT if the
lung is overdistended and perfusion is decreased.
Although driving pressure and end-inspiratory plateau
pressure were within the protective range, mechanical power was
found to be slightly high andmight have promoted lung injury (25).
In patients undergoing prone positioning, PaO2/FIO2 improvement
was followed by an increase in Crs, suggesting recruitment and
aeration of previously collapsed alveoli. In our study, mortality was
similar to that reported in other studies of critically ill patients with
SARS-CoV-2 pneumonia (3, 19).
This study presents some limitations. Four manual end-
inspiratory and end-expiratory pauses could not be performed
in all patients because of protective equipment shortages.
However, all patients included had at least one end-inspiratory
and end-expiratory pause done on the first day. These results
cannot be extrapolated to late SARS-CoV-2–induced ARDS.
In summary, SARS-CoV-2–induced ARDS presents with
an impairment in gas exchange and pulmonarymechanics comparable
with those of prior ARDS cohorts. However, lung perfusion in SARS-
CoV-2–induced ARDS warrants further investigation.
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Figure 1. Correlation between pulmonary mechanics and gas-exchange
abnormalities. (A) Correlation between Crs and PaO2/FIO2. (B) Correlation
between ventilatory ratio and D-dimer concentration. (C ) Correlation
between plateau pressure and ventilatory ratio. (D) Correlation between
PEEP and ventilatory ratio. Solid lines are the regression lines, whereas
shaded bands display 95% confidence intervals. Crs = static compliance of
the respiratory system; PaO2/FIO2 = ratio between partial pressure of oxygen
and fraction of inspired oxygen, PEEP=positive end-expiratory pressure.
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